{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:52Z","timestamp":1787841292532,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:p>Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream for treating external genital and perianal warts. In our report, two Chinese males at the ages of 25 and 22 years were treated with imiquimod 5% cream for recurrent condyloma accuminatum, three times per week for 18 and 12. weeks, respectively. Depigmentation were noted and gradually enlarged in the treated areas after the two patients discontinued imiquimod. Therefore, clinicians should be made aware of the possible pigmentary changes associated with application of this cream.<\/jats:p>","DOI":"10.4103\/0019-5154.82501","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T00:54:09Z","timestamp":1309395249000},"page":"335-336","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM"],"prefix":"10.4103","volume":"56","author":[{"given":"Ruzhi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Bengbu Medical College, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210 029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250920","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-4632.2004.02318.x","article-title":"Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis","volume":"44","author":"Majewski","year":"2005","journal-title":"Int J Dermatol"},{"key":"R2-20250920","first-page":"74","article-title":"Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod","volume":"33","author":"Mashiah","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"R3-20250920","first-page":"342","article-title":"Genital vitiligo-like depigmentation following use of imiquimod 5% cream","volume":"18","author":"Serr\u00e3o","year":"2008","journal-title":"Eur J Dermatol"},{"key":"R4-20250920","first-page":"844","article-title":"Vitiligo-like hypopigmentation with poliosis following treatment of superficial basal cell carcinoma with imiquimod","volume":"34","author":"Jacob","year":"2008","journal-title":"Dermatol Surg"},{"key":"R5-20250920","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0378-6323.37065","article-title":"Imiquimod-induced vitiligo-like depigmentation","volume":"73","author":"Senel","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R6-20250920","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5070\/D32KR0D81X","article-title":"Imiquimod-induced vitiligo","volume":"13","author":"Al-Dujaili","year":"2007","journal-title":"Dermatol Online J"},{"key":"R7-20250920","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2004.10.861","article-title":"Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts","volume":"52","author":"Brown","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R8-20250920","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1468-3083.2006.01533.x","article-title":"Imiquimod-induced vitiligo in a patient with genital warts","volume":"20","author":"Stefanaki","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R9-20250920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.2002.04945.x","article-title":"Imiquimod: A potential role in dermatology?","volume":"147","author":"Eedy","year":"2002","journal-title":"Br J Dermatol"},{"key":"R10-20250920","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin Exp Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201156030-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:48Z","timestamp":1787838528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201156030-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-5154.82501","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2009-10-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}